Rapid diagnostics Astek Diagnostics is building a urine-based test capable of confirming bacterial infections and determining antibiotic sensitivity within an hour, presenting a clear sales angle to healthcare providers seeking faster decision support and improved patient throughput.

Expansion opportunities The Jiddu Platform targets multiple specimen types (urine, CSF, wound effluent, blood), which broadens addressable markets across hospital departments such as emergency, ICU, infectious disease, and urology, enabling cross-selling of rapid testing solutions.

Strategic partnerships Existing collaborations with SC2i and MRR Children's Hospital, plus ongoing academic and hospital partnerships, create entry points for pilot programs, validation studies, and reference sites that can accelerate market adoption and credibility.

Funding momentum Recent and multiple TEDCO investments demonstrate investor confidence and potential for grant-supported pilots, which can be leveraged to secure hospital procurement funding and expand commercialization activities.

competitive positioning Positioning against peers in rapid antibiotic sensitivity testing, with measurable speed and potential cost savings, provides a clear value proposition for health systems seeking to reduce antibiotic misuse, shorten hospital stays, and lower overall treatment costs.